Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

68.55 -2.28 (-3.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,769,106
Open 70.64
Bid (Size) 67.69 (2)
Ask (Size) 69.53 (2)
Prev. Close 70.83
Today's Range 68.52 - 70.79
52wk Range 50.35 - 83.95
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
Via ACCESSWIRE
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool

Performance

YTD
+4.74%
+4.74%
1 Month
-14.82%
-14.82%
3 Month
+7.85%
+7.85%
6 Month
+10.37%
+10.37%
1 Year
+7.38%
+7.38%

More News

Read More
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
Cracking The Code: Understanding Analyst Reviews For Incyte
Via Benzinga
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
From Incyte
Via Business Wire
Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
Via Benzinga
Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review
Via Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nasdaq Reverses Losses Amid Nvidia Fanfare
Via Talk Markets
Gold Moves Higher; Medtronic Posts Upbeat Results
Via Benzinga
Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday?
Via Benzinga
Topics Energy
Exposures Fossil Fuels
What's Going On With Incyte Shares Tuesday?
Via Benzinga
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Via Benzinga
Nasdaq Gains 100 Points; Lowe's Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
Via Investor's Business Daily
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.